Compendia listing gaps for oncology access before label expansion

An oncologist wants to prescribe a drug for an off-label indication supported by a phase 3 readout presented at ASCO but not yet reflected in any CMS-recognized compendium. The pharmacy benefit manager denies the claim. The patient waits. The manufacturer loses a quarter or more of utilization in that tumor type until the compendium catches up.

This scenario plays out regularly in oncology. CMS recognizes five compendia for determining medically accepted indications of drugs and biologics used in anticancer chemotherapeutic regimens: the NCCN Drugs and Biologics Compendium, AHFS Drug Information (AHFS-DI), Elsevier/Gold Standard Clinical Pharmacology, Truven Health Analytics Micromedex DrugDex, and Wolters Kluwer Lexi-Drugs. Commercial payers use these same compendia — but not uniformly, and not always at the same evidence thresholds. The gap between emerging clinical evidence and compendia listing is one of the most consequential access barriers in oncology, and it is a gap that market access teams can anticipate and manage if they understand the system.

This article is for market access leads, medical affairs liaisons, HEOR teams, and oncology commercial teams responsible for ensuring that payer coverage keeps pace with clinical evidence. It maps the compendia landscape, identifies where gaps occur, and provides an operational framework for managing them.

The compendia system: how it works and why it matters

CMS-recognized compendia for anticancer therapy

Under Section 1861(t)(2) of the Social Security Act and 42 CFR § 414.930, Medicare must cover off-label uses of anticancer chemotherapeutic regimens if they are supported by a citation in at least one CMS-recognized compendium. CMS currently recognizes five:

Per CMS guidance in the Medicare Benefit Policy Manual (Pub 100-02, Chapter 15, Section 50.4.5), a use is identified as medically accepted if: the indication is Category 1 or 2A in NCCN, or Class I, IIa, or IIb in DrugDex; or the narrative text in AHFS or Clinical Pharmacology is supportive. A use is not medically accepted if: the indication is Category 3 in NCCN or Class III in DrugDex; or the narrative text is "not supportive."

Critically, the complete absence of narrative text on a use is considered neither supportive nor non-supportive — meaning that if a drug-indication pair is simply not yet listed, it falls into a coverage gray zone that payers may resolve either way.

Medicare vs. Medicaid compendia recognition

The five compendia listed above apply to Medicare coverage determinations. Medicaid operates under a different statutory framework (42 USC 1396r-8(k)(6)) that originally recognized only three compendia: AHFS-DI, USP-DI, and DRUGDEX. USP-DI is no longer published, creating ongoing uncertainty about which successors states recognize. Some states accept DrugPoints as a successor to USP-DI; others do not. This means that an off-label use covered under Medicare may not be covered under Medicaid in certain states, and market access teams planning launch need to address both programs separately.

NCCN Compendium: the dominant force

The NCCN Compendium is the most influential compendium for oncology coverage decisions. Avalere Health's analysis of commercial payers' use of compendia found that the NCCN Compendium is referenced by both public and private insurers, including CMS and UnitedHealthcare, as an authoritative reference for oncology coverage policy. Avalere's 2025 dashboard tracks 32 of the top 50 payers, covering 209 million lives — a 65% increase from the prior year's 127 million — demonstrating the growing scale and importance of the commercial payer compendia landscape.

NCCN Compendium entries are extracted directly from the NCCN Clinical Practice Guidelines in Oncology. This means:

• A drug-indication pair cannot appear in the Compendium until the relevant NCCN Guidelines panel has reviewed the evidence and voted on a recommendation.
• The Compendium is updated continuously as guidelines are revised, but each update requires panel review — typically at scheduled meetings two to three times per year per tumor type.
• NCCN Categories of Evidence and Consensus determine the strength of the recommendation. Category 1 is based on high-level evidence with uniform NCCN consensus. Category 2A is based on lower-level evidence with uniform consensus. Category 2B is based on lower-level evidence with non-uniform consensus (but at least a majority). Category 3 reflects major disagreement.

Some Medicare Administrative Contractors (MACs) — including CGS Administrators — have stated they consider NCCN Category 2B indications to meet Medicare benefit category requirements, even though CMS's IOM does not formally include 2B in the medically accepted definition. This creates variability across jurisdictions.

AHFS and Clinical Pharmacology: narrative-based listings

Unlike NCCN's category-based rating system, AHFS and Clinical Pharmacology use narrative text reviews. AHFS employs a transparent process: its Oncology Expert Committee reviews potential off-label oncology uses, which may be identified through internal literature surveillance or submitted via external request. The committee evaluates the evidence and determines whether the use is medically accepted.

AHFS is authorized by statute (Section 1861 of the Social Security Act) and approved by CMS as an official compendium. Its listings carry weight in Medicare coverage determinations, but the narrative format means that coverage depends on the specific language used — and updates may lag behind new evidence publications by several months.

Where compendia listing gaps occur

Gap 1: Evidence presented but not yet compendium-listed

A drug shows positive phase 3 results at a major oncology meeting (ASCO, ESMO, AACR). The data are publicly available and may be published in a peer-reviewed journal. But:

• The NCCN panel has not yet met to review the data.
• AHFS has not received or processed an external request for the indication.
• Clinical Pharmacology has not completed its literature review cycle.

Timeline: Typically 3 to 9 months from data presentation to NCCN guideline inclusion, and potentially longer for AHFS or Clinical Pharmacology narrative reviews.

Gap 2: FDA approval granted but compendia not yet updated

FDA approves a supplemental NDA or BLA for a new oncology indication. The label is updated on DailyMed. But the compendia are not automatically updated to match. Each compendium has its own review cycle and editorial process.

Timeline: NCCN typically updates within one to two guideline publication cycles after FDA approval. AHFS and Clinical Pharmacology may take longer because their review processes are independent of FDA action.

Gap 3: Positive compendium listing but payer policy not updated

Even after a compendium lists an off-label indication as medically accepted, individual payers must update their medical policies to reflect the new listing. Payers use different compendia as primary references, apply different evidence thresholds, and update policies on different schedules.

Avalere's dashboard of commercial payers' use of oncology compendia shows that payers vary in which compendia they reference, how they weight conflicting ratings across compendia, and what evidence categories trigger automatic coverage versus manual review. A drug may be listed as Category 2A in NCCN but still face prior authorization or step therapy requirements from a specific payer.

Timeline: 1 to 6 months after compendium listing for a payer to update its formal coverage policy, if it updates at all.

Gap 4: Evidence category below payer threshold

NCCN Category 2B indications are supported by evidence and require a panel majority consensus, but they are not uniformly covered. Some MACs cover 2B indications; others do not. Commercial payers may require additional clinical documentation or limit coverage to patients who meet specific criteria.

A drug with a Category 2B listing may have coverage in some jurisdictions and denials in others, creating a patchwork access landscape that market access teams must navigate region by region.

Gap 5: Compendia listing for one regimen but not another

A drug may be listed in NCCN for a specific line of therapy or in combination with a specific regimen, but not for the combination that a physician actually wants to prescribe. For example, a drug may be listed as Category 1 for first-line use with drug A but only Category 2A for first-line use with drug B. If the prescribing physician chooses the Category 2A regimen, the payer may impose additional requirements.

Gap 6: Category 3 or non-supportive listing creates a negative barrier

If any one compendium lists a use as not indicated, it can override a positive listing in another compendium. Per CMS guidance, "if a use is specifically identified as not indicated in one or more of the compendia," the off-label use is not supported. This means that a single negative compendium rating can block coverage even if other compendia are favorable.

The strategic implication is significant: submitting to all five compendia simultaneously can backfire. If one compendium evaluates the evidence less favorably and issues a non-supportive rating, that negative listing can override positive ratings from the other four. Market access teams should assess which compendia are most likely to give a favorable rating based on their evidence-weighting methodologies before deciding where to submit. A targeted submission strategy — prioritizing compendia whose review processes and evidence thresholds align with the available data — can reduce the risk of a negative override.

Operational framework for managing compendia listing gaps

Pre-launch: evidence generation and compendia submission planning

• Map the compendium landscape for the target tumor type. Identify which compendia are most influential with the top 10 payers by covered lives.
• Plan compendia submissions in parallel with FDA submissions. NCCN accepts data submissions from manufacturers, and AHFS accepts external off-label use requests. Submit data packages to compendia as early as possible in the review cycle.
• Identify the target NCCN category for each planned indication. If the evidence base supports only Category 2B at launch, anticipate payer pushback and prepare supplementary evidence packages.
• Engage NCCN panel members through medical science liaisons (within legal and compliance boundaries) to ensure awareness of upcoming data readouts.

At FDA approval: immediate compendia activation

• On the day of FDA approval for a new indication, confirm that the updated label is posted on DailyMed and Drugs@FDA.
• Submit updated data packages to all five CMS-recognized compendia with the FDA approval letter and updated prescribing information.
• For NCCN, request expedited review if the guideline panel meeting schedule allows.
• For AHFS, submit an external off-label use request via email to AHFS at ahfs@ashp.org with the subject line "Off-label Use Request."
• For Clinical Pharmacology and Micromedex DrugDex, contact the editorial teams directly with the new indication data.

Post-approval: monitoring and escalation

• Track each compendium's listing status for the new indication weekly during the first 90 days after approval.
• Identify payers that have not updated coverage policies within 60 days of compendium listing and initiate targeted payer engagement.
• For denials based on compendia gaps, support appeals with peer-reviewed literature citations as permitted under CMS guidance (Pub 100-02, Chapter 15, Section 50.4.5.D).
• Monitor NCCN panel meeting schedules and agendas to anticipate when guideline updates will be published.
• Track compendia rating changes for competitor products, as a new competitor listing can shift payer expectations for the therapeutic class.

Ongoing: denial pattern analysis

• Maintain a log of coverage denials attributed to compendia gaps, segmented by payer, tumor type, line of therapy, and compendium cited.
• Use denial data to prioritize compendia engagement and payer policy update outreach.
• Share denial patterns with medical affairs to inform evidence generation priorities and future data readout planning.
• Avalere's compendia dashboard can be used to filter by compendium rating (e.g., NCCN Category 2B) and assess coverage variations across payers.

The role of peer-reviewed literature in the gap period

CMS guidance provides a secondary coverage pathway: if a use is not listed in any compendium, contractors may still cover it if they determine from a review of peer-reviewed literature that it is a medically accepted indication. However, this requires:

• Submission of full articles, not abstracts, for contractor review.
• The articles must appear in one of the CMS-designated peer-reviewed journals, which include JAMA, NEJM, The Lancet, Journal of Clinical Oncology, Blood, Annals of Oncology, and approximately 20 others.
• Contractors evaluate the literature against four criteria: whether the clinical characteristics of the beneficiary are adequately represented in the study, whether the regimen is adequately represented, whether outcomes are clinically meaningful, and whether the study design is appropriate.
• The evidence must not be contradicted by any compendium's "not indicated" listing.

Market access teams should prepare literature-based coverage packages for the gap period between evidence presentation and compendium listing. These packages should include the primary clinical trial publication from a CMS-recognized journal, relevant meta-analyses, and any supportive real-world evidence studies.

What to monitor next

• NCCN guideline update schedules for each tumor type: panels meet two to three times per year, and guideline revisions are published on a rolling basis.
• FDA oncology approval trends: 2025 saw multiple new oncology drug approvals including ziftomenib (NPM1-mutated AML), revumenib (NPM1-mutated AML), and zongertinib (HER2-mutated NSCLC), all of which require compendium listing for full payer coverage.
• CMS compendium recognition updates: CMS has authority under Section 1861(t)(2) to add or remove compendia from the authoritative list.
• Avalere's updated commercial payer compendia dashboard, which tracks payer-specific evidence ratings and can support denial analysis and evidence generation strategy.
• Companion diagnostic (CDx) availability: several 2025 oncology approvals did not have a CDx assay available at the time of drug approval, which can create an additional access barrier even after compendium listing.
• AI-assisted compendia updates: NCCN is enhancing its Compendium with improved search functionality and template integration, which could accelerate listing timelines.

Sources

• CMS. Medicare Benefit Policy Manual, Chapter 15, Section 50.4.5: Off-Label Use of Anti-Cancer Drugs and Biologicals. Pub 100-02. cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R96BP.pdf
• CMS. Determination of Approved and Accepted Off-Label Drug Indications. Medicare Administrative Contractor article. med.noridianmedicare.com/web/jeb/topics/drugs-biologicals-injections/determination-of-approved-and-accepted-off-label-drug-indications
• NCCN. Drugs and Biologics Compendium. nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia
• AHFS. Off-Label Review Process. ahfs.ashp.org/off-label-review.aspx
• CGS Administrators. Off-Label Use of Drugs and Biologicals for Anti-Cancer Chemotherapeutic Regimen. Medicare Coverage Article A58113. cms.gov/medicare-coverage-database/view/article.aspx?articleid=58113
• National Government Services. LCD: Drugs and Biologicals, Coverage of, for Label and Off-Label Uses (L33394). cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33394
• Avalere Health. Updated Resource: Commercial Payers' Use of Oncology Compendia. 2025. advisory.avalerehealth.com/insights/new-resource-commercial-payers-use-of-oncology-compendia
• ASCO Post. New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024, and November 19, 2025. December 10, 2025. ascopost.com/issues/december-10-2025/new-fda-approved-oncology-drugs-and-label-updates-between-december-1-2024-and-november-19-2025
• Soares M. Off-Label Indications for Oncology Drug Use and Drug Compendia: History and Current Status. J Oncol Pract. 2009;5(5). pmc.ncbi.nlm.nih.gov/articles/PMC2794406
• 42 CFR § 414.930. Anticancer Chemotherapeutic Regimens.
• Social Security Act § 1861(t)(2). Definition of Medically Accepted Indication.